Why it matters

Pfizer Inc. has dramatically increased its lobbying expenditures in Q1 2025, investing $4.24 million in-house to influence federal policy on healthcare, tax, and trade issues — a 165% jump from the previous quarter.

The big picture

The pharmaceutical giant is focusing its lobbying efforts on reforming pharmacy benefit managers (PBMs), addressing the "pill penalty" in the Inflation Reduction Act, and protecting incentives for rare disease treatments.

By the numbers

  • $4.24 million: Pfizer’s Q1 2025 in-house lobbying expenditure
  • $1.6 million: Previous quarter’s spending
  • $200.53 million: Total in-house lobbying expenditures since 2008

Between the lines

The Pfizer lobbying team includes seasoned professionals with deep committee experience:

  • Paula J. Burg: Former Director of Health and Entitlements on Senate Budget Committee (2013-2014)
  • Stephen James Claeys: Former Trade Counsel on House Ways and Means Committee (2011-2017)

Key legislation targeted

Pfizer’s lobbying portfolio spans multiple bills with significant implications for the pharmaceutical industry:

  • S.832/H.R.1492: The "EPIC Act" would equalize negotiation timelines for small-molecule drugs and biologics under Medicare’s Drug Price Negotiation Program
  • S.526/S.527/S.882: Various bills targeting PBM transparency and practices
  • S.864: The "HELP Copays Act" would ensure manufacturer assistance counts toward patient deductibles
  • H.R.946: The "ORPHAN Cures Act" would modify IRA exemptions for rare disease treatments

The opposition

Pfizer faces competition from diverse stakeholders across these policy battles:

  • PBM reform: Medical associations, pharmacist groups, and AARP support reforms, while PBMs and health plans generally oppose
  • IRA amendments: Consumer advocacy groups like Public Citizen typically oppose efforts by industry groups to modify the law’s drug pricing provisions
  • Drug competition: The Association for Accessible Medicines (representing generic manufacturers) supports measures to prevent "product hopping" and other delay tactics

Other priority issues

Beyond specific legislation, Pfizer is lobbying on broader policy concerns:

  • Biosimilar access and reimbursement
  • Vaccine coverage expansions
  • Intellectual property protections, particularly regarding Bayh-Dole Act "march-in rights"
  • Digital therapeutics regulations and coverage
  • Trade agreements for medical goods and supply chain resilience

What to watch

The company’s expert lobbying team and financial commitment suggest these issues are viewed as core priorities for its business model.